SANOFI-ADR (SNY)
US80105N1054 - ADR
Why Cytokinetics Stock Was a Nearly 5% Winner Today
In a market where value is scarce, NASDAQ:SNY offers a refreshing opportunity with its solid fundamentals.
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva and Sanofi are partnered on a drug to treat inflammatory bowel disease. The drug showed "best-in-class potential" in midstage testing.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
On Tuesday, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug
Why NASDAQ:SNY qualifies as a good dividend investing stock.
Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY).
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
One of these players has split its stock in the past. The other one hasn't.
Why Sanofi Stock Flew Higher on Friday
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
Sanofi (SNY) Q3 2024 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2024.
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
The company also hiked its profit outlook for the year and expects single-digit growth.
